| scholarly article | Q13442814 |
| P50 | author | David S Roos | Q56394669 |
| P2093 | author name string | M K Bhopale | |
| M E Fichera | |||
| P2860 | cites work | Chloroplast ribosomes and protein synthesis | Q24634608 |
| In vitro effects of four macrolides (roxithromycin, spiramycin, azithromycin [CP-62,993], and A-56268) on Toxoplasma gondii | Q28359823 | ||
| Assessment of therapy for toxoplasma encephalitis. The TE Study Group | Q33454020 | ||
| Comparison of mutants of Toxoplasma gondii selected for resistance to azithromycin, spiramycin, or clindamycin | Q33746997 | ||
| Localization of azithromycin in Toxoplasma gondii-infected cells | Q33755229 | ||
| Antibiotic resistance mutations in the chloroplast 16S and 23S rRNA genes of Chlamydomonas reinhardtii: correlation of genetic and physical maps of the chloroplast genome | Q33955799 | ||
| Inhibition of cytoplasmic and organellar protein synthesis in Toxoplasma gondii. Implications for the target of macrolide antibiotics. | Q34196036 | ||
| The parasitophorous vacuole membrane surrounding intracellular Toxoplasma gondii functions as a molecular sieve | Q34980590 | ||
| New micromethod to study the effect of antimicrobial agents on Toxoplasma gondii: comparison of sulfadoxine and sulfadiazine individually and in combination with pyrimethamine and study of clindamycin, metronidazole, and cyclosporin A. | Q35639477 | ||
| Toxoplasmic encephalitis in AIDS. | Q35810946 | ||
| Parasiticidal effect of clindamycin on Toxoplasma gondii grown in cultured cells and selection of a drug-resistant mutant | Q35836436 | ||
| Current recommendations and future prospects in the treatment of toxoplasmosis | Q38756395 | ||
| In vitro assessment of antimicrobial agents against Toxoplasma gondii | Q39050049 | ||
| Evaluation of the efficacy and safety of clindamycin plus pyrimethamine for induction and maintenance therapy of toxoplasmic encephalitis in AIDS. | Q39123475 | ||
| Effect of clindamycin on intracellular replication, protein synthesis, and infectivity of Toxoplasma gondii | Q39883651 | ||
| Molecular tools for genetic dissection of the protozoan parasite Toxoplasma gondii | Q40501292 | ||
| Interaction of the antibiotics clindamycin and lincomycin with Escherichia coli 23S ribosomal RNA. | Q40534214 | ||
| Treatment of toxoplasmic encephalitis in patients with AIDS. A randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine. The California Collaborative Treatment Group | Q40738767 | ||
| Interactions between Toxoplasma gondii and its mammalian host cells | Q40788924 | ||
| Tandemly repeated genes encode nucleoside triphosphate hydrolase isoforms secreted into the parasitophorous vacuole of Toxoplasma gondii. | Q42695544 | ||
| Sulphadiazine desensitization in patients with AIDS and cerebral toxoplasmosis | Q43889281 | ||
| Have malaria parasites three genomes? | Q47996291 | ||
| Treatment of central nervous system toxoplasmosis with pyrimethamine/sulfadiazine combination in 35 patients with the acquired immunodeficiency syndrome. Efficacy of long-term continuous therapy | Q48134771 | ||
| Organisation and expression of small subunit ribosomal RNA genes encoded by a 35-kilobase circular DNA in Plasmodium falciparum | Q48212630 | ||
| Toxoplasma gondii: secretion of a potent nucleoside triphosphate hydrolase into the parasitophorous vacuole | Q72798338 | ||
| Toxoplasmic encephalitis in patients with the acquired immunodeficiency syndrome. Members of the ACTG 077p/ANRS 009 Study Team | Q72914757 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Toxoplasma gondii | Q131003 |
| clindamycin | Q422273 | ||
| P304 | page(s) | 1530-1537 | |
| P577 | publication date | 1995-07-01 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | In vitro assays elucidate peculiar kinetics of clindamycin action against Toxoplasma gondii | |
| P478 | volume | 39 |
| Q35865145 | 'FAS't inhibition of malaria |
| Q35142236 | A Toxoplasma gondii mutant highlights the importance of translational regulation in the apicoplast during animal infection |
| Q30044413 | A dual-targeted aminoacyl-tRNA synthetase in Plasmodium falciparum charges cytosolic and apicoplast tRNACys |
| Q47808765 | A genetic screen in rodent malaria parasites identifies five new apicoplast putative membrane transporters, one of which is essential in human malaria parasites. |
| Q47823727 | A plastid organelle as a drug target in apicomplexan parasites. |
| Q39673553 | A plastid segregation defect in the protozoan parasite Toxoplasma gondii |
| Q34722217 | A type II pathway for fatty acid biosynthesis presents drug targets in Plasmodium falciparum |
| Q43936787 | An rRNA mutation identifies the apicoplast as the target for clindamycin in Toxoplasma gondii |
| Q38811119 | Anti-Toxoplasma activity and impact evaluation of lyophilization, hot molding process, and gamma-irradiation techniques on CLH-PLGA intravitreal implants. |
| Q37726477 | Antibiotics for human toxoplasmosis: a systematic review of randomized trials |
| Q35840382 | Antimalarial combinations |
| Q39720138 | Antiplasmodial thiostrepton derivatives: proteasome inhibitors with a dual mode of action. |
| Q33702247 | Apicomplexan plastids as drug targets |
| Q36018552 | Apicoplast-targeting antibacterials inhibit the growth of Babesia parasites |
| Q36791777 | Apoptosis-like cell death pathways in the unicellular parasite Toxoplasma gondii following treatment with apoptosis inducers and chemotherapeutic agents: a proof-of-concept study |
| Q33687965 | Biochemical peculiarities and drug targets in Cryptosporidium parvum: lessons from other coccidian parasites |
| Q40611245 | Cerebral Toxoplasmosis |
| Q27973797 | Characterization of two malaria parasite organelle translation elongation factor G proteins: the likely targets of the anti-malarial fusidic acid |
| Q34904340 | Chemistry and biology of macrolide antiparasitic agents |
| Q28547065 | Ciprofloxacin Derivatives Affect Parasite Cell Division and Increase the Survival of Mice Infected with Toxoplasma gondii |
| Q38138018 | Clinical features and treatment of ocular toxoplasmosis |
| Q26782581 | Clinically Available Medicines Demonstrating Anti-Toxoplasma Activity |
| Q64091493 | Combination of Clindamycin and Azithromycin as Alternative Treatment for Toxoplasma gondii Encephalitis |
| Q43615024 | DNA replication and daughter cell budding are not tightly linked in the protozoan parasite Toxoplasma gondii |
| Q33953731 | Daughter cell assembly in the protozoan parasite Toxoplasma gondii |
| Q91989306 | Delayed death in the malaria parasite Plasmodium falciparum is caused by disruption of prenylation-dependent intracellular trafficking |
| Q90265315 | Discovery of Novel Anti-cryptosporidial Activities From Natural Products by in vitro High-Throughput Phenotypic Screening |
| Q42125453 | Disruption of the expression of a non-coding RNA significantly impairs cellular differentiation in Toxoplasma gondii |
| Q46330680 | Double-stranded RNA specific to adenosine kinase and hypoxanthine-xanthine-guanine-phosphoribosyltransferase retards growth of Toxoplasma gondii |
| Q30806899 | Dynamics of Toxoplasma gondii differentiation |
| Q34051207 | Dynamics of the Toxoplasma gondii inner membrane complex. |
| Q89972997 | Evaluating the GCN5b bromodomain as a novel therapeutic target against the parasite Toxoplasma gondii |
| Q24643897 | Extrachromosomal DNA in the Apicomplexa |
| Q40616078 | Fitness effects of DHFR-TS mutations associated with pyrimethamine resistance in apicomplexan parasites |
| Q36729982 | Garcinol Inhibits GCN5-Mediated Lysine Acetyltransferase Activity and Prevents Replication of the Parasite Toxoplasma gondii |
| Q59178755 | Gene knock-outs and allelic replacements in Toxoplasma gondii: HXGPRT as a selectable marker for hit-and-run mutagenesis |
| Q30994423 | Genomic data reveal Toxoplasma gondii differentiation mutants are also impaired with respect to switching into a novel extracellular tachyzoite state |
| Q73296757 | Growth of and competition between Neospora caninum and Toxoplasma gondii in vitro |
| Q92720553 | HIV-Related Cerebral Toxoplasmosis Revisited: Current Concepts and Controversies of an Old Disease |
| Q34725225 | High-throughput growth assay for Toxoplasma gondii using yellow fluorescent protein |
| Q61806726 | Host Cell Metabolism Contributes to Delayed-Death Kinetics of Apicoplast Inhibitors in Toxoplasma gondii |
| Q43982266 | Identification and characterization of differentiation mutants in the protozoan parasite Toxoplasma gondii |
| Q33872108 | Impact of a plastid-bearing endocytobiont on apicomplexan genomes. |
| Q40425386 | In vitro evaluation of the effectiveness of the macrolide rokitamycin and chlorpromazine against Acanthamoeba castellanii |
| Q32062673 | In vitro quantitative analysis of (3)H-uracil incorporation by Sarcocytis neurona to determine efficacy of anti-protozoal agents |
| Q37109789 | Infection with Toxoplasma gondii results in dysregulation of the host cell cycle |
| Q45296496 | Intravitreal clindamycin plus dexamethasone versus classic oral therapy in toxoplasmic retinochoroiditis: a prospective randomized clinical trial |
| Q35648606 | Lincomycin, clindamycin and their applications |
| Q35964967 | Lincosamides: chemical structure, biosynthesis, mechanism of action, resistance, and applications |
| Q37868313 | Lower respiratory tract infections in cats: reaching beyond empirical therapy |
| Q28538285 | Lysine acetyltransferase GCN5b interacts with AP2 factors and is required for Toxoplasma gondii proliferation |
| Q36577718 | Macrolides and associated antibiotics based on similar mechanism of action like lincosamides in malaria |
| Q38068970 | Medicinal potential of ciprofloxacin and its derivatives |
| Q37749058 | Metabolic pathways in the apicoplast of apicomplexa. |
| Q35213000 | Mining the Plasmodium genome database to define organellar function: what does the apicoplast do? |
| Q36095096 | Multiple antibiotics exert delayed effects against the Plasmodium falciparum apicoplast |
| Q33815675 | Myosin-dependent cell-cell communication controls synchronicity of division in acute and chronic stages of Toxoplasma gondii |
| Q37992089 | New antibacterials for the treatment of toxoplasmosis; a patent review |
| Q53537659 | New comprehension of the apicoplast of Sarcocystis by transmission electron tomography. |
| Q58828669 | Non-Antifolate Antibiotics: Clindamycin, Doxycycline, Azithromycin and Fosmidomycin |
| Q46645614 | Organellar dynamics during the cell cycle of Toxoplasma gondii. |
| Q33718406 | Origin, targeting, and function of the apicomplexan plastid |
| Q38972996 | Pantothenic acid biosynthesis in the parasite Toxoplasma gondii: a target for chemotherapy. |
| Q27312274 | Phosphatidylinositol 3-monophosphate is involved in toxoplasma apicoplast biogenesis |
| Q34182794 | Phosphorylation of eukaryotic initiation factor-2α promotes the extracellular survival of obligate intracellular parasite Toxoplasma gondii |
| Q39422863 | Protein Degradation Systems as Antimalarial Therapeutic Targets |
| Q34593987 | Recent advances in the search for new anti-coccidial drugs |
| Q39142182 | Regulation of ATG8 membrane association by ATG4 in the parasitic protist Toxoplasma gondii |
| Q30043256 | Selective inhibition of apicoplast tryptophanyl-tRNA synthetase causes delayed death in Plasmodium falciparum |
| Q34488213 | Subcellular localization of acetyl-CoA carboxylase in the apicomplexan parasite Toxoplasma gondii |
| Q48022900 | Targeted Phenotypic Screening in Plasmodium falciparum and Toxoplasma gondii Reveals Novel Modes of Action of Medicines for Malaria Venture Malaria Box Molecules. |
| Q35805373 | Targeted disruption of Toxoplasma gondii serine protease inhibitor 1 increases bradyzoite cyst formation in vitro and parasite tissue burden in mice |
| Q78168444 | Targeted reduction of nucleoside triphosphate hydrolase by antisense RNA inhibits Toxoplasma gondii proliferation |
| Q52348641 | TgTKL1 Is a Unique Plant-Like Nuclear Kinase That Plays an Essential Role in Acute Toxoplasmosis. |
| Q44898755 | The apicoplast as a potential therapeutic target in Toxoplasma and other apicomplexan parasites: some additional thoughts |
| Q43906091 | The apicoplast as a potential therapeutic target in and other apicomplexan parasites |
| Q46386660 | The apicoplast of Plasmodium falciparum is translationally active. |
| Q34533262 | The apicoplast: A plastid in Plasmodium falciparum and other apicomplexan parasites |
| Q29544118 | The apicoplast: a new member of the plastid family |
| Q56911719 | The effects of nitidine chloride and camptothecin on the growth of Babesia and Theileria parasites |
| Q42725813 | The in vitro development of Neospora caninum bradyzoites |
| Q27349108 | The motility of a human parasite, Toxoplasma gondii, is regulated by a novel lysine methyltransferase |
| Q34038501 | The plastid in Apicomplexa: what use is it? |
| Q36293658 | The plastid of Toxoplasma gondii is divided by association with the centrosomes |
| Q37942263 | Therapy for ocular toxoplasmosis. |
| Q37703340 | Toxoplasma gondii AP2IX-4 Regulates Gene Expression during Bradyzoite Development |
| Q33765729 | Toxoplasma gondii bradyzoites form spontaneously during sporozoite-initiated development |
| Q74769472 | Toxoplasma gondii in vitro culture for experimentation |
| Q35538988 | Toxoplasma gondii nucleus coding apicoplast protein ACP synthesis and trafficking in delayed death |
| Q31028361 | Translocation of ribosomal protein P0 onto the Toxoplasma gondii tachyzoite surface |
| Q77377954 | Treatment protocol determines the efficacy of clindamycin in acute murine toxoplasmosis |
| Q30080014 | Tropical infectious diseases: metabolic maps and functions of the Plasmodium falciparum apicoplast |
| Q35137900 | Use of Toxoplasma gondii expressing beta-galactosidase for colorimetric assessment of drug activity in vitro |
| Q48015411 | Validation of Putative Apicoplast-Targeting Drugs Using a Chemical Supplementation Assay in Cultured Human Malaria Parasites. |
| Q30045658 | Validation of isoleucine utilization targets in Plasmodium falciparum |
Search more.